Arcutis Biotherapeutics (ARQT)

Executive Summary

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on topical treatments for immune-mediated dermatological conditions. Its lead product, ZORYVE (roflumilast) cream 0.3%, is approved for plaque psoriasis, and ZORYVE foam is approved for seborrheic dermatitis, leveraging a novel PDE-4 inhibitor mechanism with once-daily dosing. The company is expanding its pipeline into high-unmet-need indications including atopic dermatitis (Phase 3 completed), hidradenitis suppurativa (Phase 2 recruiting), and scalp psoriasis. Commercial execution has shown steady prescription growth, though competition from established topical therapies and JAK inhibitors remains a risk. With a strong cash position and multiple late-stage catalysts, Arcutis is positioned to broaden its label and drive long-term value.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 topline data for roflumilast foam in hidradenitis suppurativa60% success
• Q4 2026NDA submission for roflumilast cream in atopic dermatitis75% success
• Q2 2026Potential FDA approval for ZORYVE foam in scalp psoriasis85% success